Press Releases

Month Year

Get News Alerts by Email

Sep 6, 2022

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular...
Aug 23, 2022

C2N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings

C2N Diagnostics and Eisai Inc. today announced the Companies have entered into a memorandum of understanding that will seek to build awareness about how blood-based assays for cognitive...
Aug 18, 2022

Eisai Inc. Reinforces Commitment to Collaboration and Innovation to Support Patients and Communities Through New U.S. Headquarters

State-of-the-art Eisai US hhceco Center underscores New Jersey as the premier life science hub NUTLEY, N.J., Aug. 18, 2022 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai...
- Photos 1
Aug 4, 2022

Eisai Partners with Baseball Legend to Help Support People Living with Liver Cancer

Campaign Provides Educational Resources on Liver Cancer and Encourages People to Make Some Daily Adjustments to Help Support Liver Health NUTLEY, N.J., Aug. 4, 2022 /PRNewswire/ -- Baseball legend...
- Photos 2
Aug 3, 2022

Eisai Presents New Findings On Lecanemab's Investigational Subcutaneous Formulation And Modeling Simulation Of APOE4 Genotype On ARIA-E Incidence At The Alzheimer's Association International Conference (AAIC) 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced that...

Show per page

Open a printable version of this page
Email the URL of this page to a friend